Candida glabrata among Candida spp. from environmental health practitioners of a Brazilian Hospital
- PMID: 26991302
- PMCID: PMC4874588
- DOI: 10.1016/j.bjm.2015.05.001
Candida glabrata among Candida spp. from environmental health practitioners of a Brazilian Hospital
Abstract
The incidence of the species Candida albicans and non-albicans Candida was evaluated in a Brazilian Tertiary Hospital from the environment and health practitioners. In a 12-month period we had a total positivity of 19.65% of Candida spp. The most recurring non-albicans Candida species was C. glabrata (37.62%), generally considered a species of low virulence, but with a higher mortality rate than C. albicans. Subsequently, C. parapsilosis (25.74%) and C. tropicalis (16.86%) were the second and third most commonly isolated species. Considering the total samples collected from the emergency room and from the inpatient and the pediatric sector, 19.10% were positive for Candida spp., with the predominance of non-albicans Candida species (89.42%). The high percentage of positivity occurred in the hands (24.32%) and the lab coats (21.88%) of the health care assistants. No sample of C. albicans presented a profile of resistance to the drugs. All the non-albicans Candida species presented a decreased susceptibility to miconazole and itraconazole, but they were susceptible to nystatin. Most of the isolates were susceptible to fluconazole and amphotericin B. As expected, a high resistance rate was observed in C. glabrata and C. krusei, which are intrinsically less susceptible to this antifungal agent. The contamination of environmental surfaces by Candida spp. through hand touching may facilitate the occurrence of Candida infections predominantly in immunocompromised patients. In addition to that, the antifungal agents used should be carefully evaluated considering local epidemiologic trends in Candida spp. infections, so that therapeutic choices may be better guided.
Keywords: Antifungal drugs; Candida glabrata; Candida spp.; Hospital environment; Non-albicans Candida species.
Copyright © 2016. Published by Elsevier Editora Ltda.
References
-
- Nucci M., Colombo A.L. Risk factors of breakthrough candidemia. Eur J Clin Microbiol Infect Dis. 2002;21(3):209–211. - PubMed
-
- Tortorano A.M., Peman J., Bernhardt H. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol. 2004;23(4):317–322. - PubMed
-
- Chi H.W., Yang Y.S., Shang S.T. Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome. J Microbiol Immunol Infect. 2011;44(5):369–375. - PubMed
-
- Chow J.K., Golan Y., Ruthazer R. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the Intensive Care unit. Clin Infect Dis. 2008;46(8):1206–1213. - PubMed
-
- Colombo A.L., Guimarães T. Epidemiologia das infecções hematogênicas por Candida spp. Rev Soc Bras Med Trop. 2003;36(5):599–607. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous